Women now make up the majority of GLP-1 medication users, yet much of the clinical research was conducted in mixed or male-dominant populations. As use of medications like Wegovy (semaglutide) and Zepbound (tirzepatide) continues to grow, a clearer picture is emerging of how these drugs interact with the unique hormonal landscape of women's bodies — and what women specifically need to know before starting.

How GLP-1 Receptor Agonists Work

GLP-1 (glucagon-like peptide-1) is an incretin hormone naturally released by your gut in response to food. It signals the pancreas to release insulin, slows gastric emptying (so you feel full longer), and acts on the brain's appetite centers to reduce hunger and food cravings.

GLP-1 receptor agonist medications mimic and amplify these effects. The current leading options include:

  • Semaglutide (Wegovy, Ozempic) — a GLP-1 agonist approved for chronic weight management (Wegovy) and type 2 diabetes (Ozempic)
  • Tirzepatide (Zepbound, Mounjaro) — a dual GIP/GLP-1 agonist with even greater average weight loss in clinical trials; approved for obesity (Zepbound) and diabetes (Mounjaro)

Both are administered as weekly subcutaneous injections with gradual dose escalation to minimize side effects.

How GLP-1s Affect Female Hormones

The hormonal effects of GLP-1 medications in women are multifaceted and, in many cases, beneficial:

Insulin and Metabolic Hormones

GLP-1s significantly improve insulin sensitivity and reduce fasting insulin levels — a benefit with wide-ranging hormonal effects. Since elevated insulin drives excess androgen production in conditions like PCOS, reducing insulin resistance can normalize testosterone and SHBG (sex hormone-binding globulin) levels, restoring more normal hormonal balance.

Estrogen and Fat Tissue

Fat tissue is a major site of estrogen conversion (aromatization). As body fat decreases, estrogen production from fat tissue decreases — which can alter the estrogen environment in both pre- and postmenopausal women. This effect is generally beneficial in the context of obesity-related estrogen excess but warrants monitoring in some individuals.

Reproductive Hormones and the Menstrual Cycle

Some women report changes to their menstrual cycles during GLP-1 therapy — particularly early in treatment as significant weight loss occurs. In women with PCOS, menstrual regularity often improves. In others, cycle changes may be temporary adaptations. Always report significant menstrual changes to your provider.

GLP-1 Medications and PCOS

Polycystic ovary syndrome (PCOS) affects approximately 1 in 10 women of reproductive age, and insulin resistance is a central driver in the majority of cases. GLP-1 receptor agonists address this directly and are showing significant promise for women with PCOS:

  • Weight reduction — even modest weight loss (5–10%) can significantly improve PCOS symptoms and hormone levels
  • Improved insulin sensitivity — reduces hyperinsulinemia-driven androgen excess
  • Reduced testosterone and free androgen index — associated with reductions in hirsutism and acne
  • Restored ovulation — several studies have shown improved ovulatory function in anovulatory women with PCOS using GLP-1 therapy
  • Improved fertility outcomes — in combination with lifestyle changes, GLP-1s may support fertility in women with PCOS-related subfertility

Clinical guidelines are increasingly recognizing GLP-1 medications as an important option for women with PCOS who have not achieved adequate results with lifestyle modification and metformin.

GLP-1 Medications and Menopause

Menopause is associated with significant metabolic changes: increased central adiposity, insulin resistance, reduced lean muscle mass, and greater cardiovascular risk. GLP-1 medications address many of these changes directly:

  • Reduce visceral (abdominal) fat, which is especially prevalent post-menopause
  • Improve fasting glucose and insulin sensitivity that often worsen after estrogen decline
  • Support weight management at a life stage when weight gain is particularly common
  • May reduce hot flash frequency and severity, possibly through central nervous system effects (research ongoing)
  • Cardiovascular protection — the SUSTAIN and SELECT trials demonstrated meaningful cardiovascular risk reduction

Women in perimenopause and menopause may respond differently to GLP-1 dosing. Some clinicians note that menopausal women may require dose optimization and should prioritize resistance training alongside GLP-1 therapy to preserve muscle mass.

GLP-1s and Fertility: A Critical Consideration

GLP-1 medications are not recommended during pregnancy or while trying to conceive. This is a critically important point for women of reproductive age.

Animal studies have raised concerns about potential developmental effects. Current clinical guidance recommends:

  • Discontinue GLP-1 therapy at least 2 months before attempting conception (this allows for clearance from the body)
  • Use reliable contraception while on GLP-1 medications
  • Note that improved fertility from PCOS treatment can lead to unexpected pregnancies — contraception is essential
  • Discontinue immediately if pregnancy is discovered and consult your provider

Additionally, oral contraceptives may have reduced absorption due to GLP-1's effects on gastric emptying. Women using oral contraceptives should consider backup contraception or switch to a non-oral form.

Wegovy vs. Zepbound: Which Is Better for Women?

Both medications are effective for weight loss, but there are meaningful differences:

Wegovy (Semaglutide 2.4 mg weekly)

  • FDA-approved for chronic weight management in adults with BMI ≥30 or ≥27 with a weight-related condition
  • Average weight loss in STEP trials: ~15% of body weight over 68 weeks
  • Strong cardiovascular outcome data (SELECT trial)
  • Well-established safety profile with several years of real-world use

Zepbound (Tirzepatide 5–15 mg weekly)

  • FDA-approved for chronic weight management; also targets GIP receptors in addition to GLP-1
  • Average weight loss in SURMOUNT trials: ~20–22% of body weight at highest doses
  • Emerging evidence suggests particularly strong effects on insulin resistance and metabolic markers
  • Some evidence suggests beneficial effects on PCOS-related hormones, though less data than semaglutide

There is no definitive answer that one is universally "better" for women — the best choice depends on individual health history, insurance coverage, and provider recommendation.

Side Effects Women Should Watch For

The most common side effects of GLP-1 medications affect the gastrointestinal tract and are generally dose-dependent:

  • Nausea (most common, especially early in treatment)
  • Vomiting
  • Diarrhea or constipation
  • Acid reflux
  • Fatigue during dose escalation

Women may be somewhat more likely than men to experience GI side effects, possibly due to differences in gastric emptying rates. Strategies to minimize nausea include eating smaller, lower-fat meals; avoiding lying down after eating; and escalating doses slowly.

Additional considerations specific to women:

  • Hair loss (telogen effluvium) — rapid weight loss can trigger temporary hair shedding; ensure adequate protein intake (at least 1.2–1.6g per kg of body weight) to minimize this
  • Muscle mass — women tend to lose more lean mass with weight loss; resistance training and protein intake are critical
  • Bone density — significant weight loss can affect bone mineral density; calcium, vitamin D, and weight-bearing exercise are important protective measures

When GLP-1 Medications Are NOT Recommended for Women

GLP-1 receptor agonists are contraindicated or require caution in certain situations:

  • Pregnancy or planned pregnancy in the near term
  • Breastfeeding — insufficient safety data
  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple endocrine neoplasia syndrome type 2 (MEN 2)
  • History of pancreatitis — discuss carefully with your provider
  • Severe gastroparesis — GLP-1s slow gastric emptying further
  • Active eating disorder history — should be carefully evaluated; medication alone is not appropriate without mental health support

Dosing and What to Expect

Both Wegovy and Zepbound use a gradual dose escalation schedule — typically increasing the dose every 4 weeks — to minimize GI side effects. Most women reach their maintenance dose within 16–20 weeks.

Realistic expectations for women on GLP-1 therapy:

  • Significant weight loss typically begins within the first 4–8 weeks
  • Maximum effects are seen at 52–68 weeks; weight loss continues beyond this point for many individuals
  • Weight regain commonly occurs when medication is discontinued; many women use GLP-1s long-term
  • Results are significantly enhanced by pairing medication with dietary changes and physical activity